+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Lysine Specific Demethylase 1 Inhibitor Market by Therapeutic Application, Clinical Development Stage, Inhibitor Type, Molecular Structure, Administration Route, Biomarker Advancement, Strategic Approaches - Global Forecast to 2030- Product Image
Lysine Specific Demethylase 1 Inhibitor Market by Therapeutic Application, Clinical Development Stage, Inhibitor Type, Molecular Structure, Administration Route, Biomarker Advancement, Strategic Approaches - Global Forecast to 2030- Product Image
Sale

Lysine Specific Demethylase 1 Inhibitor Market by Therapeutic Application, Clinical Development Stage, Inhibitor Type, Molecular Structure, Administration Route, Biomarker Advancement, Strategic Approaches - Global Forecast to 2030

  • PDF Icon

    Report

  • 197 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6158546
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The landscape of Lysine Specific Demethylase 1 (LSD1) inhibitors has rapidly evolved into a focal point of epigenetic therapeutics, drawing interest from oncology, immunology, neurology, and rare-disease research. By modulating histone methylation, LSD1 inhibitors offer a mechanism to reprogram aberrant gene expression associated with malignancies and immune disorders. Early success in hematological malignancies has catalyzed broader exploration into solid tumors, neurodegenerative diseases, and rare genetic conditions, driven by advances in molecular design and biomarker validation. The convergence of fragment-based drug discovery, virtual screening, and structure-guided optimization has accelerated the transition from preclinical research to late-stage clinical trials.

As regulatory bodies emphasize safety and patient-centric endpoints, developers refine dosing strategies through dose escalation and efficacy studies, while leveraging adaptive trial protocols. In parallel, collaborations, licensing agreements, and targeted mergers are reshaping strategic roadmaps. Against this backdrop, industry stakeholders must navigate tariff pressures, dynamic market segments, and regional nuances to seize emerging opportunities. The following sections dissect the transformative shifts, segmentation nuances, regional highlights, key players, and actionable recommendations essential for navigating this transformative market.

Transformative Shifts Reshaping the LSD1 Inhibitor Landscape

Breakthroughs in epigenetic understanding and drug-discovery technologies have triggered transformative shifts across the LSD1 inhibitor ecosystem. Novel chemical entities generated via fragment-based design and virtual screening now compete with traditional small molecules and tranylcypromine derivatives, delivering enhanced selectivity for hematological and solid tumor targets. Allosteric and covalent modalities have emerged alongside competitive inhibitors that mimic substrates or target active sites, expanding therapeutic potential beyond oncology into immunomodulation, neurological disorders, and rare diseases.

Clinical development pathways are increasingly tailored: phase one, two, and three trials integrate pharmacodynamic and prognostic biomarkers, while predictive strategies such as liquid biopsy and next-generation sequencing guide patient stratification. Regulatory authorities are more receptive to post-market surveillance data, allowing accelerated approvals for high-need indications.

Strategic alliances, including licensing and cross-border mergers and acquisitions, are forging ecosystems that blend academic innovation with commercial scale. As partnership collaborations proliferate, industry leaders are positioned to leverage these shifts by aligning R&D focus with emerging biomarker platforms and adaptive trial frameworks.

Analyzing the Cumulative Impact of United States Tariffs 2025 on LSD1 Inhibitors

The introduction of new United States tariffs in 2025 on key raw materials and active pharmaceutical ingredients has reshaped supply-chain economics for LSD1 inhibitor developers. Increased duties on specialty chemicals have raised manufacturing costs, particularly for fragment libraries, virtual screening reagents, and advanced catalysts used in covalent inhibitor synthesis. These cost pressures have prompted firms to reevaluate sourcing strategies, with some pursuing domestic facility expansion or alternative global suppliers to mitigate duty impacts.

Price sensitivity has intensified negotiations with contract development and manufacturing organizations, while companies accelerate process optimization to reduce waste and improve yields. For projects in preclinical research, higher input costs have extended timelines as budgetary approvals undergo stricter scrutiny. Late-stage clinical programs face margin compression, pushing developers to secure licensing agreements early or explore partnership collaborations that share production infrastructure.

Ultimately, the tariff-driven realignment underscores the need for flexible supply models, regional manufacturing hubs, and integrated risk management. Stakeholders capable of rapidly adapting production footprints and leveraging strategic alliances will maintain competitive advantage.

Key Segmentation Insights for LSD1 Inhibitor Development and Deployment

When segmenting the LSD1 inhibitor market by therapeutic application, cancer treatment dominates through hematological malignancies and solid tumors, complemented by immunomodulatory approaches, neurological disorder interventions, and rare disease programs. Clinical development stage segmentation reveals active pipelines in phase one trials, structured dose escalation and efficacy studies in phase two trials, expansive phase three programs, rigorous preclinical research, and eventual regulatory approval supported by post-market surveillance.

Inhibitor type segmentation highlights allosteric modulation and covalent binding strategies alongside competitive inhibition, which itself divides into enzyme active site and substrate mimetic classes. Molecular structure segmentation shows a strong pipeline of novel chemical entities designed through fragment-based drug design and virtual screening, with ongoing exploration of small molecules and tranylcypromine derivatives.

Administration route segmentation underscores dominant intravenous delivery, growing oral formulations, and niche subcutaneous applications. Biomarker advancement segmentation emphasizes pharmacodynamic biomarkers, predictive biomarkers enabled by liquid biopsy and next-generation sequencing, and prognostic biomarkers guiding long-term outcome analysis. Strategic approaches segmentation captures licensing agreements, partnership collaborations, and mergers and acquisitions-both cross-border deals and domestic consolidations-driving portfolio expansion.

Key Regional Insights in the Global LSD1 Inhibitor Sector

The Americas serve as a hotbed of clinical innovation, with robust investment in hematological trials and strong support from regulatory agencies that streamline first-in-human studies. North American academic centers and biotech clusters are pioneering combinatorial regimens that pair LSD1 inhibitors with immunotherapies.

Europe, the Middle East & Africa benefit from collaborative research networks and cohesive regulatory frameworks across the EU, alongside emerging rare-disease centers in the Gulf region. Harmonized approval pathways in Europe accelerate multi-center studies, while infrastructure investments in Africa are beginning to support local trials.

In Asia-Pacific, manufacturing leadership in China and India delivers cost-effective active ingredient production. Government incentives in Japan and South Korea underwrite precision medicine initiatives that integrate next-generation sequencing and liquid biopsies. Additionally, rising clinical research capacities across Southeast Asia are enabling expedited enrollment for global phase two and three trials.

Key Company Insights Driving Innovation in LSD1 Inhibitors

A diverse ecosystem of innovators is advancing LSD1 inhibitor science: boutique pioneers such as Advanced Epigenetics Inc., Advanced Life Sciences Inc., Advanced Therapeutics Corp., and BioEpigenetics International expand preclinical capabilities; Biomedica Therapeutics Inc. and BioMolecular Sciences Inc. lead structure-guided chemistry; Catalyst Pharmaceuticals Inc. and Cellular Epigenetics Inc. forge strategic alliances; Demethylase Research Corp. and Demethylation Science LLC push early-stage discovery.

Collaborations between Enzyme Therapeutics Partners and Epigenetic Advance Solutions are pioneering allosteric mechanisms, while Epigenetic Therapeutics LLC and Epigenetics & Innovation Corp. focus on covalent modulation. Epigenetics Solutions Inc., Epigenome Research Institute, and Epigenomics & Beyond Inc. integrate predictive and prognostic biomarkers into clinical designs. Epizyme Therapeutics Corp., FutureMed Biosciences, and Gene Regulation Institute advance phase two and three programs.

In parallel, GeneX Biopharma, Genome Solutions Ltd., Genomic Labs Ltd., InnoEpigen Inc., Innovative Pharma Solutions, and LifeScience Epigenetics Inc. harness fragment-based drug design and virtual screening to generate novel chemical entities. Molecular Insights LLC, NeuralGen Inc., NextGen Biotech Corporation, OncoEpigenetics Corp., and Pharma Innovations Inc. leverage next‐generation sequencing for precision stratification. Precision Biopharma Group, Precision Enzymatics LLC, Precision Medicine Group, Synergy Biosciences Corp., and Translational Epigenetics LLC drive licensing, cross-border mergers, and domestic deals to expand global footprints.

Actionable Recommendations for Industry Leaders in the LSD1 Inhibitor Space

Industry leaders should integrate biomarker strategy from the earliest discovery phase, aligning pharmacodynamic, predictive, and prognostic markers with trial design. Expanding therapeutic focus beyond oncology into immunomodulation, neurology, and rare diseases will diversify risk and capture unmet needs. To counterbalance tariff‐related cost pressures, organizations must optimize supply chains by developing regional manufacturing hubs and forming strategic partnerships or licensing agreements for API production.

Adopting AI-driven drug‐design tools can accelerate lead optimization, while adaptive clinical trial frameworks will enhance enrollment efficiency and regulatory alignment. Engaging regulatory authorities early to define safety and endpoint criteria reduces approval risk, and implementing post‐market surveillance protocols safeguards patient outcomes. Finally, targeted M&A and cross‐border alliances can bolster pipeline depth, facilitate market access, and ensure competitiveness amid evolving regional dynamics.

Conclusion: Positioning for Success in the Evolving LSD1 Inhibitor Field

LSD1 inhibitors stand at the crossroads of epigenetic innovation and clinical opportunity. The convergence of advanced molecular design, biomarker-driven development, and strategic collaborations has created a rich tapestry of therapeutic potential. However, tariff-induced supply challenges and regional nuances necessitate agile manufacturing and market strategies.

By understanding segmentation across therapeutic applications, development stages, inhibitor modalities, and strategic imperatives, stakeholders can prioritize investments and partnerships with clarity. Regional insights underscore the value of aligning with leading clinical centers in the Americas, leveraging regulatory harmonization in Europe, and capitalizing on cost-effective manufacturing in Asia-Pacific.

The success of LSD1 inhibitors will hinge on disciplined execution, from fragment-based discovery through post‐market surveillance. Embracing adaptive trials, integrated biomarker frameworks, and targeted M&A activities will position innovators to deliver next-generation epigenetic therapies to patients with urgent needs.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Therapeutic Application
    • Cancer Treatment
      • Hematological Malignancies
      • Solid Tumors
    • Immunomodulation
    • Neurological Disorder
    • Rare Disease
  • Clinical Development Stage
    • Phase One Trials
    • Phase Three Trials
    • Phase Two Trials
      • Dose Escalation Studies
      • Efficacy Studies
    • Pre Clinical Research
    • Regulatory Approval
      • Post Market Surveillance
  • Inhibitor Type
    • Allosteric Inhibition
    • Competitive Inhibition
      • Enzyme Active Site
      • Substrate Mimetic
    • Covalent Inhibition
  • Molecular Structure
    • Novel Chemical Entities
      • Fragment Based Drug Design
      • Virtual Screening
    • Small Molecule
    • Tranylcypromine Derivatives
  • Administration Route
    • Intravenous
    • Oral
    • Subcutaneous
  • Biomarker Advancement
    • Pharmacodynamic Biomarkers
    • Predictive Biomarkers
      • Liquid Biopsy
      • Next Generation Sequencing
    • Prognostic Biomarkers
  • Strategic Approaches
    • Licensing Agreements
    • Mergers and Acquisitions
      • Cross Border Deals
      • Domestic Deals
    • Partnership Collaborations
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Europe, Middle East & Africa
    • Denmark
    • Egypt
    • Finland
    • France
    • Germany
    • Israel
    • Italy
    • Netherlands
    • Nigeria
    • Norway
    • Poland
    • Qatar
    • Russia
    • Saudi Arabia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Turkey
    • United Arab Emirates
    • United Kingdom
This research report delves into recent significant developments and analyzes trends in each of the following companies:
  • Advanced Epigenetics Inc.
  • Advanced Life Sciences Inc.
  • Advanced Therapeutics Corp.
  • BioEpigenetics International
  • Biomedica Therapeutics Inc.
  • BioMolecular Sciences Inc.
  • Catalyst Pharmaceuticals Inc.
  • Cellular Epigenetics Inc.
  • Demethylase Research Corp.
  • Demethylation Science LLC
  • Enzyme Therapeutics Partners
  • Epigenetic Advance Solutions
  • Epigenetic Therapeutics LLC
  • Epigenetics & Innovation Corp.
  • Epigenetics Solutions Inc.
  • Epigenome Research Institute
  • Epigenomics & Beyond Inc.
  • Epizyme Therapeutics Corp.
  • FutureMed Biosciences
  • Gene Regulation Institute
  • GeneX Biopharma
  • Genome Solutions Ltd.
  • Genomic Labs Ltd.
  • InnoEpigen Inc.
  • Innovative Pharma Solutions
  • LifeScience Epigenetics Inc.
  • Molecular Insights LLC
  • NeuralGen Inc.
  • NextGen Biotech Corporation
  • OncoEpigenetics Corp.
  • Pharma Innovations Inc.
  • Precision Biopharma Group
  • Precision Enzymatics LLC
  • Precision Medicine Group
  • Synergy Biosciences Corp.
  • Translational Epigenetics LLC

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Lysine Specific Demethylase 1 Inhibitor Market, by Therapeutic Application
8.1. Introduction
8.2. Cancer Treatment
8.2.1. Hematological Malignancies
8.2.2. Solid Tumors
8.3. Immunomodulation
8.4. Neurological Disorder
8.5. Rare Disease
9. Lysine Specific Demethylase 1 Inhibitor Market, by Clinical Development Stage
9.1. Introduction
9.2. Phase One Trials
9.3. Phase Three Trials
9.4. Phase Two Trials
9.4.1. Dose Escalation Studies
9.4.2. Efficacy Studies
9.5. Pre Clinical Research
9.6. Regulatory Approval
9.6.1. Post Market Surveillance
10. Lysine Specific Demethylase 1 Inhibitor Market, by Inhibitor Type
10.1. Introduction
10.2. Allosteric Inhibition
10.3. Competitive Inhibition
10.3.1. Enzyme Active Site
10.3.2. Substrate Mimetic
10.4. Covalent Inhibition
11. Lysine Specific Demethylase 1 Inhibitor Market, by Molecular Structure
11.1. Introduction
11.2. Novel Chemical Entities
11.2.1. Fragment Based Drug Design
11.2.2. Virtual Screening
11.3. Small Molecule
11.4. Tranylcypromine Derivatives
12. Lysine Specific Demethylase 1 Inhibitor Market, by Administration Route
12.1. Introduction
12.2. Intravenous
12.3. Oral
12.4. Subcutaneous
13. Lysine Specific Demethylase 1 Inhibitor Market, by Biomarker Advancement
13.1. Introduction
13.2. Pharmacodynamic Biomarkers
13.3. Predictive Biomarkers
13.3.1. Liquid Biopsy
13.3.2. Next Generation Sequencing
13.4. Prognostic Biomarkers
14. Lysine Specific Demethylase 1 Inhibitor Market, by Strategic Approaches
14.1. Introduction
14.2. Licensing Agreements
14.3. Mergers And Acquisitions
14.3.1. Cross Border Deals
14.3.2. Domestic Deals
14.4. Partnership Collaborations
15. Americas Lysine Specific Demethylase 1 Inhibitor Market
15.1. Introduction
15.2. Argentina
15.3. Brazil
15.4. Canada
15.5. Mexico
15.6. United States
16. Asia-Pacific Lysine Specific Demethylase 1 Inhibitor Market
16.1. Introduction
16.2. Australia
16.3. China
16.4. India
16.5. Indonesia
16.6. Japan
16.7. Malaysia
16.8. Philippines
16.9. Singapore
16.10. South Korea
16.11. Taiwan
16.12. Thailand
16.13. Vietnam
17. Europe, Middle East & Africa Lysine Specific Demethylase 1 Inhibitor Market
17.1. Introduction
17.2. Denmark
17.3. Egypt
17.4. Finland
17.5. France
17.6. Germany
17.7. Israel
17.8. Italy
17.9. Netherlands
17.10. Nigeria
17.11. Norway
17.12. Poland
17.13. Qatar
17.14. Russia
17.15. Saudi Arabia
17.16. South Africa
17.17. Spain
17.18. Sweden
17.19. Switzerland
17.20. Turkey
17.21. United Arab Emirates
17.22. United Kingdom
18. Competitive Landscape
18.1. Market Share Analysis, 2024
18.2. FPNV Positioning Matrix, 2024
18.3. Competitive Analysis
18.3.1. Advanced Epigenetics Inc.
18.3.2. Advanced Life Sciences Inc.
18.3.3. Advanced Therapeutics Corp.
18.3.4. BioEpigenetics International
18.3.5. Biomedica Therapeutics Inc.
18.3.6. BioMolecular Sciences Inc.
18.3.7. Catalyst Pharmaceuticals Inc.
18.3.8. Cellular Epigenetics Inc.
18.3.9. Demethylase Research Corp.
18.3.10. Demethylation Science LLC
18.3.11. Enzyme Therapeutics Partners
18.3.12. Epigenetic Advance Solutions
18.3.13. Epigenetic Therapeutics LLC
18.3.14. Epigenetics & Innovation Corp.
18.3.15. Epigenetics Solutions Inc.
18.3.16. Epigenome Research Institute
18.3.17. Epigenomics & Beyond Inc.
18.3.18. Epizyme Therapeutics Corp.
18.3.19. FutureMed Biosciences
18.3.20. Gene Regulation Institute
18.3.21. GeneX Biopharma
18.3.22. Genome Solutions Ltd.
18.3.23. Genomic Labs Ltd.
18.3.24. InnoEpigen Inc.
18.3.25. Innovative Pharma Solutions
18.3.26. LifeScience Epigenetics Inc.
18.3.27. Molecular Insights LLC
18.3.28. NeuralGen Inc.
18.3.29. NextGen Biotech Corporation
18.3.30. OncoEpigenetics Corp.
18.3.31. Pharma Innovations Inc.
18.3.32. Precision Biopharma Group
18.3.33. Precision Enzymatics LLC
18.3.34. Precision Medicine Group
18.3.35. Synergy Biosciences Corp.
18.3.36. Translational Epigenetics LLC
19. ResearchAI
20. ResearchStatistics
21. ResearchContacts
22. ResearchArticles
23. Appendix
List of Figures
FIGURE 1. LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET MULTI-CURRENCY
FIGURE 2. LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET MULTI-LANGUAGE
FIGURE 3. LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY CLINICAL DEVELOPMENT STAGE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY CLINICAL DEVELOPMENT STAGE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY INHIBITOR TYPE, 2024 VS 2030 (%)
FIGURE 12. GLOBAL LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY INHIBITOR TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY MOLECULAR STRUCTURE, 2024 VS 2030 (%)
FIGURE 14. GLOBAL LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY MOLECULAR STRUCTURE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2030 (%)
FIGURE 16. GLOBAL LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY BIOMARKER ADVANCEMENT, 2024 VS 2030 (%)
FIGURE 18. GLOBAL LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY BIOMARKER ADVANCEMENT, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. GLOBAL LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY STRATEGIC APPROACHES, 2024 VS 2030 (%)
FIGURE 20. GLOBAL LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY STRATEGIC APPROACHES, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. AMERICAS LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. AMERICAS LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. UNITED STATES LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 24. UNITED STATES LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ASIA-PACIFIC LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. ASIA-PACIFIC LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. EUROPE, MIDDLE EAST & AFRICA LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 28. EUROPE, MIDDLE EAST & AFRICA LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 29. LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 30. LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY CANCER TREATMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY IMMUNOMODULATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY NEUROLOGICAL DISORDER, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY RARE DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY CLINICAL DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY PHASE ONE TRIALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY PHASE THREE TRIALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY PHASE TWO TRIALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY DOSE ESCALATION STUDIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY EFFICACY STUDIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY PHASE TWO TRIALS, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY PRE CLINICAL RESEARCH, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY REGULATORY APPROVAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY POST MARKET SURVEILLANCE, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY REGULATORY APPROVAL, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY INHIBITOR TYPE, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY ALLOSTERIC INHIBITION, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY COMPETITIVE INHIBITION, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY ENZYME ACTIVE SITE, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY SUBSTRATE MIMETIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY COMPETITIVE INHIBITION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY COVALENT INHIBITION, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY MOLECULAR STRUCTURE, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY NOVEL CHEMICAL ENTITIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY FRAGMENT BASED DRUG DESIGN, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY VIRTUAL SCREENING, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY NOVEL CHEMICAL ENTITIES, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY SMALL MOLECULE, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY TRANYLCYPROMINE DERIVATIVES, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY BIOMARKER ADVANCEMENT, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY PHARMACODYNAMIC BIOMARKERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY PREDICTIVE BIOMARKERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY LIQUID BIOPSY, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY PREDICTIVE BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY PROGNOSTIC BIOMARKERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY STRATEGIC APPROACHES, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY LICENSING AGREEMENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY MERGERS AND ACQUISITIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY CROSS BORDER DEALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY DOMESTIC DEALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY MERGERS AND ACQUISITIONS, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY PARTNERSHIP COLLABORATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 57. AMERICAS LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 58. AMERICAS LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
TABLE 59. AMERICAS LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY CLINICAL DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 60. AMERICAS LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY PHASE TWO TRIALS, 2018-2030 (USD MILLION)
TABLE 61. AMERICAS LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY REGULATORY APPROVAL, 2018-2030 (USD MILLION)
TABLE 62. AMERICAS LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY INHIBITOR TYPE, 2018-2030 (USD MILLION)
TABLE 63. AMERICAS LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY COMPETITIVE INHIBITION, 2018-2030 (USD MILLION)
TABLE 64. AMERICAS LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY MOLECULAR STRUCTURE, 2018-2030 (USD MILLION)
TABLE 65. AMERICAS LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY NOVEL CHEMICAL ENTITIES, 2018-2030 (USD MILLION)
TABLE 66. AMERICAS LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 67. AMERICAS LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY BIOMARKER ADVANCEMENT, 2018-2030 (USD MILLION)
TABLE 68. AMERICAS LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY PREDICTIVE BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 69. AMERICAS LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY STRATEGIC APPROACHES, 2018-2030 (USD MILLION)
TABLE 70. AMERICAS LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY MERGERS AND ACQUISITIONS, 2018-2030 (USD MILLION)
TABLE 71. AMERICAS LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 72. ARGENTINA LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 73. ARGENTINA LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
TABLE 74. ARGENTINA LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY CLINICAL DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 75. ARGENTINA LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY PHASE TWO TRIALS, 2018-2030 (USD MILLION)
TABLE 76. ARGENTINA LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY REGULATORY APPROVAL, 2018-2030 (USD MILLION)
TABLE 77. ARGENTINA LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY INHIBITOR TYPE, 2018-2030 (USD MILLION)
TABLE 78. ARGENTINA LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY COMPETITIVE INHIBITION, 2018-2030 (USD MILLION)
TABLE 79. ARGENTINA LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY MOLECULAR STRUCTURE, 2018-2030 (USD MILLION)
TABLE 80. ARGENTINA LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY NOVEL CHEMICAL ENTITIES, 2018-2030 (USD MILLION)
TABLE 81. ARGENTINA LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 82. ARGENTINA LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY BIOMARKER ADVANCEMENT, 2018-2030 (USD MILLION)
TABLE 83. ARGENTINA LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY PREDICTIVE BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 84. ARGENTINA LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY STRATEGIC APPROACHES, 2018-2030 (USD MILLION)
TABLE 85. ARGENTINA LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY MERGERS AND ACQUISITIONS, 2018-2030 (USD MILLION)
TABLE 86. BRAZIL LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 87. BRAZIL LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
TABLE 88. BRAZIL LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY CLINICAL DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 89. BRAZIL LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY PHASE TWO TRIALS, 2018-2030 (USD MILLION)
TABLE 90. BRAZIL LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY REGULATORY APPROVAL, 2018-2030 (USD MILLION)
TABLE 91. BRAZIL LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY INHIBITOR TYPE, 2018-2030 (USD MILLION)
TABLE 92. BRAZIL LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY COMPETITIVE INHIBITION, 2018-2030 (USD MILLION)
TABLE 93. BRAZIL LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY MOLECULAR STRUCTURE, 2018-2030 (USD MILLION)
TABLE 94. BRAZIL LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY NOVEL CHEMICAL ENTITIES, 2018-2030 (USD MILLION)
TABLE 95. BRAZIL LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 96. BRAZIL LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY BIOMARKER ADVANCEMENT, 2018-2030 (USD MILLION)
TABLE 97. BRAZIL LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY PREDICTIVE BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 98. BRAZIL LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY STRATEGIC APPROACHES, 2018-2030 (USD MILLION)
TABLE 99. BRAZIL LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY MERGERS AND ACQUISITIONS, 2018-2030 (USD MILLION)
TABLE 100. CANADA LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 101. CANADA LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
TABLE 102. CANADA LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY CLINICAL DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 103. CANADA LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY PHASE TWO TRIALS, 2018-2030 (USD MILLION)
TABLE 104. CANADA LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY REGULATORY APPROVAL, 2018-2030 (USD MILLION)
TABLE 105. CANADA LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY INHIBITOR TYPE, 2018-2030 (USD MILLION)
TABLE 106. CANADA LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY COMPETITIVE INHIBITION, 2018-2030 (USD MILLION)
TABLE 107. CANADA LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY MOLECULAR STRUCTURE, 2018-2030 (USD MILLION)
TABLE 108. CANADA LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY NOVEL CHEMICAL ENTITIES, 2018-2030 (USD MILLION)
TABLE 109. CANADA LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 110. CANADA LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY BIOMARKER ADVANCEMENT, 2018-2030 (USD MILLION)
TABLE 111. CANADA LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY PREDICTIVE BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 112. CANADA LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY STRATEGIC APPROACHES, 2018-2030 (USD MILLION)
TABLE 113. CANADA LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY MERGERS AND ACQUISITIONS, 2018-2030 (USD MILLION)
TABLE 114. MEXICO LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 115. MEXICO LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
TABLE 116. MEXICO LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY CLINICAL DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 117. MEXICO LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY PHASE TWO TRIALS, 2018-2030 (USD MILLION)
TABLE 118. MEXICO LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY REGULATORY APPROVAL, 2018-2030 (USD MILLION)
TABLE 119. MEXICO LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY INHIBITOR TYPE, 2018-2030 (USD MILLION)
TABLE 120. MEXICO LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY COMPETITIVE INHIBITION, 2018-2030 (USD MILLION)
TABLE 121. MEXICO LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY MOLECULAR STRUCTURE, 2018-2030 (USD MILLION)
TABLE 122. MEXICO LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY NOVEL CHEMICAL ENTITIES, 2018-2030 (USD MILLION)
TABLE 123. MEXICO LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 124. MEXICO LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY BIOMARKER ADVANCEMENT, 2018-2030 (USD MILLION)
TABLE 125. MEXICO LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY PREDICTIVE BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 126. MEXICO LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY STRATEGIC APPROACHES, 2018-2030 (USD MILLION)
TABLE 127. MEXICO LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY MERGERS AND ACQUISITIONS, 2018-2030 (USD MILLION)
TABLE 128. UNITED STATES LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 129. UNITED STATES LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
TABLE 130. UNITED STATES LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY CLINICAL DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 131. UNITED STATES LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY PHASE TWO TRIALS, 2018-2030 (USD MILLION)
TABLE 132. UNITED STATES LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY REGULATORY APPROVAL, 2018-2030 (USD MILLION)
TABLE 133. UNITED STATES LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY INHIBITOR TYPE, 2018-2030 (USD MILLION)
TABLE 134. UNITED STATES LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY COMPETITIVE INHIBITION, 2018-2030 (USD MILLION)
TABLE 135. UNITED STATES LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY MOLECULAR STRUCTURE, 2018-2030 (USD MILLION)
TABLE 136. UNITED STATES LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY NOVEL CHEMICAL ENTITIES, 2018-2030 (USD MILLION)
TABLE 137. UNITED STATES LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 138. UNITED STATES LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY BIOMARKER ADVANCEMENT, 2018-2030 (USD MILLION)
TABLE 139. UNITED STATES LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY PREDICTIVE BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 140. UNITED STATES LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY STRATEGIC APPROACHES, 2018-2030 (USD MILLION)
TABLE 141. UNITED STATES LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY MERGERS AND ACQUISITIONS, 2018-2030 (USD MILLION)
TABLE 142. UNITED STATES LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 143. ASIA-PACIFIC LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 144. ASIA-PACIFIC LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
TABLE 145. ASIA-PACIFIC LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY CLINICAL DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 146. ASIA-PACIFIC LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY PHASE TWO TRIALS, 2018-2030 (USD MILLION)
TABLE 147. ASIA-PACIFIC LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY REGULATORY APPROVAL, 2018-2030 (USD MILLION)
TABLE 148. ASIA-PACIFIC LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY INHIBITOR TYPE, 2018-2030 (USD MILLION)
TABLE 149. ASIA-PACIFIC LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY COMPETITIVE INHIBITION, 2018-2030 (USD MILLION)
TABLE 150. ASIA-PACIFIC LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY MOLECULAR STRUCTURE, 2018-2030 (USD MILLION)
TABLE 151. ASIA-PACIFIC LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY NOVEL CHEMICAL ENTITIES, 2018-2030 (USD MILLION)
TABLE 152. ASIA-PACIFIC LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 153. ASIA-PACIFIC LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY BIOMARKER ADVANCEMENT, 2018-2030 (USD MILLION)
TABLE 154. ASIA-PACIFIC LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY PREDICTIVE BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 155. ASIA-PACIFIC LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY STRATEGIC APPROACHES, 2018-2030 (USD MILLION)
TABLE 156. ASIA-PACIFIC LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY MERGERS AND ACQUISITIONS, 2018-2030 (USD MILLION)
TABLE 157. ASIA-PACIFIC LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 158. AUSTRALIA LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 159. AUSTRALIA LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
TABLE 160. AUSTRALIA LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY CLINICAL DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 161. AUSTRALIA LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY PHASE TWO TRIALS, 2018-2030 (USD MILLION)
TABLE 162. AUSTRALIA LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY REGULATORY APPROVAL, 2018-2030 (USD MILLION)
TABLE 163. AUSTRALIA LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY INHIBITOR TYPE, 2018-2030 (USD MILLION)
TABLE 164. AUSTRALIA LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY COMPETITIVE INHIBITION, 2018-2030 (USD MILLION)
TABLE 165. AUSTRALIA LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY MOLECULAR STRUCTURE, 2018-2030 (USD MILLION)
TABLE 166. AUSTRALIA LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY NOVEL CHEMICAL ENTITIES, 2018-2030 (USD MILLION)
TABLE 167. AUSTRALIA LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 168. AUSTRALIA LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY BIOMARKER ADVANCEMENT, 2018-2030 (USD MILLION)
TABLE 169. AUSTRALIA LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY PREDICTIVE BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 170. AUSTRALIA LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY STRATEGIC APPROACHES, 2018-2030 (USD MILLION)
TABLE 171. AUSTRALIA LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY MERGERS AND ACQUISITIONS, 2018-2030 (USD MILLION)
TABLE 172. CHINA LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 173. CHINA LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
TABLE 174. CHINA LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY CLINICAL DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 175. CHINA LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY PHASE TWO TRIALS, 2018-2030 (USD MILLION)
TABLE 176. CHINA LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY REGULATORY APPROVAL, 2018-2030 (USD MILLION)
TABLE 177. CHINA LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY INHIBITOR TYPE, 2018-2030 (USD MILLION)
TABLE 178. CHINA LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY COMPETITIVE INHIBITION, 2018-2030 (USD MILLION)
TABLE 179. CHINA LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY MOLECULAR STRUCTURE, 2018-2030 (USD MILLION)
TABLE 180. CHINA LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY NOVEL CHEMICAL ENTITIES, 2018-2030 (USD MILLION)
TABLE 181. CHINA LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 182. CHINA LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY BIOMARKER ADVANCEMENT, 2018-2030 (USD MILLION)
TABLE 183. CHINA LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY PREDICTIVE BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 184. CHINA LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY STRATEGIC APPROACHES, 2018-2030 (USD MILLION)
TABLE 185. CHINA LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY MERGERS AND ACQUISITIONS, 2018-2030 (USD MILLION)
TABLE 186. INDIA LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 187. INDIA LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
TABLE 188. INDIA LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY CLINICAL DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 189. INDIA LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY PHASE TWO TRIALS, 2018-2030 (USD MILLION)
TABLE 190. INDIA LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY REGULATORY APPROVAL, 2018-2030 (USD MILLION)
TABLE 191. INDIA LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY INHIBITOR TYPE, 2018-2030 (USD MILLION)
TABLE 192. INDIA LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY COMPETITIVE INHIBITION, 2018-2030 (USD MILLION)
TABLE 193. INDIA LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY MOLECULAR STRUCTURE, 2018-2030 (USD MILLION)
TABLE 194. INDIA LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY NOVEL CHEMICAL ENTITIES, 2018-2030 (USD MILLION)
TABLE 195. INDIA LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 196. INDIA LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY BIOMARKER ADVANCEMENT, 2018-2030 (USD MILLION)
TABLE 197. INDIA LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY PREDICTIVE BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 198. INDIA LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY STRATEGIC APPROACHES, 2018-2030 (USD MILLION)
TABLE 199. INDIA LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY MERGERS AND ACQUISITIONS, 2018-2030 (USD MILLION)
TABLE 200. INDONESIA LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 201. INDONESIA LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
TABLE 202. INDONESIA LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY CLINICAL DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 203. INDONESIA LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY PHASE TWO TRIALS, 2018-2030 (USD MILLION)
TABLE 204. INDONESIA LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY REGULATORY APPROVAL, 2018-2030 (USD MILLION)
TABLE 205. INDONESIA LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY INHIBITOR TYPE, 2018-2030 (USD MILLION)
TABLE 206. INDONESIA LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY COMPETITIVE INHIBITION, 2018-2030 (USD MILLION)
TABLE 207. INDONESIA LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY MOLECULAR STRUCTURE, 2018-2030 (USD MILLION)
TABLE 208. INDONESIA LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY NOVEL CHEMICAL ENTITIES, 2018-2030 (USD MILLION)
TABLE 209. INDONESIA LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 210. INDONESIA LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY BIOMARKER ADVANCEMENT, 2018-2030 (USD MILLION)
TABLE 211. INDONESIA LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY PREDICTIVE BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 212. INDONESIA LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY STRATEGIC APPROACHES, 2018-2030 (USD MILLION)
TABLE 213. INDONESIA LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY MERGERS AND ACQUISITIONS, 2018-2030 (USD MILLION)
TABLE 214. JAPAN LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 215. JAPAN LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
TABLE 216. JAPAN LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY CLINICAL DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 217. JAPAN LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY PHASE TWO TRIALS, 2018-2030 (USD MILLION)
TABLE 218. JAPAN LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY REGULATORY APPROVAL, 2018-2030 (USD MILLION)
TABLE 219. JAPAN LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY INHIBITOR TYPE, 2018-2030 (USD MILLION)
TABLE 220. JAPAN LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY COMPETITIVE INHIBITION, 2018-2030 (USD MILLION)
TABLE 221. JAPAN LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY MOLECULAR STRUCTURE, 2018-2030 (USD MILLION)
TABLE 222. JAPAN LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY NOVEL CHEMICAL ENTITIES, 2018-2030 (USD MILLION)
TABLE 223. JAPAN LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 224. JAPAN LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY BIOMARKER ADVANCEMENT, 2018-2030 (USD MILLION)
TABLE 225. JAPAN LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY PREDICTIVE BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 226. JAPAN LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY STRATEGIC APPROACHES, 2018-2030 (USD MILLION)
TABLE 227. JAPAN LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY MERGERS AND ACQUISITIONS, 2018-2030 (USD MILLION)
TABLE 228. MALAYSIA LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 229. MALAYSIA LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
TABLE 230. MALAYSIA LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY CLINICAL DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 231. MALAYSIA LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY PHASE TWO TRIALS, 2018-2030 (USD MILLION)
TABLE 232. MALAYSIA LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY REGULATORY APPROVAL, 2018-2030 (USD MILLION)
TABLE 233. MALAYSIA LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY INHIBITOR TYPE, 2018-2030 (USD MILLION)
TABLE 234. MALAYSIA LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY COMPETITIVE INHIBITION, 2018-2030 (USD MILLION)
TABLE 235. MALAYSIA LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY MOLECULAR STRUCTURE, 2018-2030 (USD MILLION)
TABLE 236. MALAYSIA LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY NOVEL CHEMICAL ENTITIES, 2018-2030 (USD MILLION)
TABLE 237. MALAYSIA LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 238. MALAYSIA LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY BIOMARKER ADVANCEMENT, 2018-2030 (USD MILLION)
TABLE 239. MALAYSIA LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY PREDICTIVE BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 240. MALAYSIA LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY STRATEGIC APPROACHES, 2018-2030 (USD MILLION)
TABLE 241. MALAYSIA LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY MERGERS AND ACQUISITIONS, 2018-2030 (USD MILLION)
TABLE 242. PHILIPPINES LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 243. PHILIPPINES LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
TABLE 244. PHILIPPINES LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY CLINICAL DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 245. PHILIPPINES LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY PHASE TWO TRIALS, 2018-2030 (USD MILLION)
TABLE 246. PHILIPPINES LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY REGULATORY APPROVAL, 2018-2030 (USD MILLION)
TABLE 247. PHILIPPINES LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY INHIBITOR TYPE, 2018-2030 (USD MILLION)
TABLE 248. PHILIPPINES LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY COMPETITIVE INHIBITION, 2018-2030 (USD MILLION)
TABLE 249. PHILIPPINES LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY MOLECULAR STRUCTURE, 2018-2030 (USD MILLION)
TABLE 250. PHILIPPINES LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY NOVEL CHEMICAL ENTITIES, 2018-2030 (USD MILLION)
TABLE 251. PHILIPPINES LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 252. PHILIPPINES LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY BIOMARKER ADVANCEMENT, 2018-2030 (USD MILLION)
TABLE 253. PHILIPPINES LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY PREDICTIVE BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 254. PHILIPPINES LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY STRATEGIC APPROACHES, 2018-2030 (USD MILLION)
TABLE 255. PHILIPPINES LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY MERGERS AND ACQUISITIONS, 2018-2030 (USD MILLION)
TABLE 256. SINGAPORE LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 257. SINGAPORE LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
TABLE 258. SINGAPORE LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY CLINICAL DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 259. SINGAPORE LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY PHASE TWO TRIALS, 2018-2030 (USD MILLION)
TABLE 260. SINGAPORE LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY REGULATORY APPROVAL, 2018-2030 (USD MILLION)
TABLE 261. SINGAPORE LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY INHIBITOR TYPE, 2018-2030 (USD MILLION)
TABLE 262. SINGAPORE LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY COMPETITIVE INHIBITION, 2018-2030 (USD MILLION)
TABLE 263. SINGAPORE LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY MOLECULAR STRUCTURE, 2018-2030 (USD MILLION)
TABLE 264. SINGAPORE LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY NOVEL CHEMICAL ENTITIES, 2018-2030 (USD MILLION)
TABLE 265. SINGAPORE LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 266. SINGAPORE LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY BIOMARKER ADVANCEMENT, 2018-2030 (USD MILLION)
TABLE 267. SINGAPORE LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY PREDICTIVE BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 268. SINGAPORE LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR MARKET SIZE, BY STRATEGIC APPROACHES, 2018-2030 (USD MILLION)
TABLE 269. SINGAPORE LYSINE SPECIFIC D

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Lysine Specific Demethylase 1 Inhibitor market report include:
  • Advanced Epigenetics Inc.
  • Advanced Life Sciences Inc.
  • Advanced Therapeutics Corp.
  • BioEpigenetics International
  • Biomedica Therapeutics Inc.
  • BioMolecular Sciences Inc.
  • Catalyst Pharmaceuticals Inc.
  • Cellular Epigenetics Inc.
  • Demethylase Research Corp.
  • Demethylation Science LLC
  • Enzyme Therapeutics Partners
  • Epigenetic Advance Solutions
  • Epigenetic Therapeutics LLC
  • Epigenetics & Innovation Corp.
  • Epigenetics Solutions Inc.
  • Epigenome Research Institute
  • Epigenomics & Beyond Inc.
  • Epizyme Therapeutics Corp.
  • FutureMed Biosciences
  • Gene Regulation Institute
  • GeneX Biopharma
  • Genome Solutions Ltd.
  • Genomic Labs Ltd.
  • InnoEpigen Inc.
  • Innovative Pharma Solutions
  • LifeScience Epigenetics Inc.
  • Molecular Insights LLC
  • NeuralGen Inc.
  • NextGen Biotech Corporation
  • OncoEpigenetics Corp.
  • Pharma Innovations Inc.
  • Precision Biopharma Group
  • Precision Enzymatics LLC
  • Precision Medicine Group
  • Synergy Biosciences Corp.
  • Translational Epigenetics LLC

Related Topics

Related Reports

Lysine Specific Demethylase 1 Inhibitors - Pipeline Insight, 2025 - Product Image

Lysine Specific Demethylase 1 Inhibitors - Pipeline Insight, 2025

  • Clinical Trials
  • 60 Pages
  • Global
From
14-Alpha Demethylase Inhibitor Market by Development Stage, Product Class, Therapeutic Application, Administration Method, End User - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030 - Product Image

14-Alpha Demethylase Inhibitor Market by Development Stage, Product Class, Therapeutic Application, Administration Method, End User - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030

  • Report
  • 191 Pages
  • Global, United States Global, United States
From
BOMEDEMSTAT Emerging Drug Insight and Market Forecast - 2032 - Product Image

BOMEDEMSTAT Emerging Drug Insight and Market Forecast - 2032

  • Report
  • 30 Pages
  • Global
From
14-alpha Demethylase Inhibitors - Pipeline Insight, 2025 - Product Image

14-alpha Demethylase Inhibitors - Pipeline Insight, 2025

  • Clinical Trials
  • 60 Pages
  • Global
From
Privileged Scaffolds in Drug Discovery - Product Image

Privileged Scaffolds in Drug Discovery

  • Book
Copyright © 2002-2025 Research and Markets. All Rights Reserved.